Quinlan Paul T

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 17. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5 of 17
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
Oruka Therapeutics, Inc.General CounselOption exercisenothing paid10,000 sharesSep 21, 2026Oruka Therapeutics, Inc.General Counselnothing paidExercise · Sep 21Option exercise10,000Sep 21, 2026
Oruka Therapeutics, Inc.General CounselOpen-market sell$254,1962,667 sharesSep 21, 2026Oruka Therapeutics, Inc.General Counsel$254,196Sell · Sep 21Open-market sell2,667Sep 21, 2026
Oruka Therapeutics, Inc.General CounselOpen-market sell$56,760601 sharesSep 21, 2026Oruka Therapeutics, Inc.General Counsel$56,760Sell · Sep 21Open-market sell601Sep 21, 2026
Oruka Therapeutics, Inc.General CounselOpen-market sell$357,5923,832 sharesSep 21, 2026Oruka Therapeutics, Inc.General Counsel$357,592Sell · Sep 21Open-market sell3,832Sep 21, 2026
Oruka Therapeutics, Inc.General CounselOpen-market sell$267,8702,900 sharesSep 21, 2026Oruka Therapeutics, Inc.General Counsel$267,870Sell · Sep 21Open-market sell2,900Sep 21, 2026